Literature DB >> 22840917

Extended-release niacin acutely suppresses postprandial triglyceridemia.

M Haris U Usman1, Arman Qamar, Ramprasad Gadi, Scott Lilly, Harsh Goel, Jaison Hampson, Megan L Mucksavage, Grace A Nathanson, Daniel J Rader, Richard L Dunbar.   

Abstract

OBJECTIVE: Postprandial triglyceridemia predicts cardiovascular events. Niacin might lower postprandial triglycerides by restricting free fatty acids. Immediate-release niacin reduced postprandial triglycerides, but extended-release niacin failed to do so when dosed the night before a fat challenge. The study aims were to determine whether extended-release niacin dosed before a fat challenge suppresses postprandial triglycerides and whether postprandial triglycerides are related to free fatty acid restriction.
METHODS: A double-blinded, placebo-controlled, random-order crossover experiment was performed, in which healthy volunteers took 2 g extended-release niacin or placebo 1 hour before heavy cream. We sampled blood over 12 hours and report triglycerides and free fatty acid as means ± standard deviation for incremental area under the curve (AUC) and nadir.
RESULTS: By combining 43 fat challenges from 22 subjects, postprandial triglycerides incremental AUC was +312 ± 200 mg/dL*h on placebo versus +199 ± 200 mg/dL*h on extended-release niacin (33% decrease, P=.02). The incremental nadir for free fatty acid was -0.07 ± 0.15 mmol/L on placebo versus -0.27 ± 0.13 mmol/L on extended-release niacin (P<.0001), and free fatty acid incremental AUC decreased from +2.9 ± 1.5 mmol/L*h to +1.5 ± 1.5 mmol/L*h on extended-release niacin (20% decrease, P=.0015). The incremental AUC for triglycerides was strongly related to the post-dose decrease in free fatty acid (r = +0.58, P=.0007).
CONCLUSIONS: Given right before a fat meal, even a single dose of extended-release niacin suppresses postprandial triglyceridemia. This establishes that postprandial triglycerides suppression is an acute pharmacodynamic effect of extended-release niacin, probably the result of marked free fatty acid restriction. Further study is warranted to determine whether mealtime dosing would augment the clinical efficacy of extended-release niacin therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840917      PMCID: PMC4170918          DOI: 10.1016/j.amjmed.2012.03.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  48 in total

Review 1.  Methodology for studying postprandial lipid metabolism.

Authors:  D Lairon; J Lopez-Miranda; C Williams
Journal:  Eur J Clin Nutr       Date:  2007-04-25       Impact factor: 4.016

Review 2.  Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

Authors:  Martina Lukasova; Julien Hanson; Sorin Tunaru; Stefan Offermanns
Journal:  Trends Pharmacol Sci       Date:  2011-09-22       Impact factor: 14.819

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

4.  Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid.

Authors:  Carlos Hernandez; Matthew Molusky; Yaqiang Li; Siming Li; Jiandie D Lin
Journal:  Cell Metab       Date:  2010-10-06       Impact factor: 27.287

Review 5.  Postprandial lipemia--effect of lipid-lowering drugs.

Authors:  Fredrik Karpe
Journal:  Atheroscler Suppl       Date:  2002-05       Impact factor: 3.235

6.  Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.

Authors:  W Wang; A Basinger; R A Neese; B Shane; S A Myong; M Christiansen; M K Hellerstein
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-03       Impact factor: 4.310

7.  Seeing red: flushing out instigators of niacin-associated skin toxicity.

Authors:  Richard L Dunbar; Joel M Gelfand
Journal:  J Clin Invest       Date:  2010-07-26       Impact factor: 14.808

8.  Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Authors:  Brett Lauring; Andrew K P Taggart; James R Tata; Richard Dunbar; Luzelena Caro; Kang Cheng; Jayne Chin; Steven L Colletti; Josee Cote; Sauzanne Khalilieh; Jiajun Liu; Wen-Lin Luo; Alexandra A Maclean; Laurence B Peterson; Adam B Polis; Waheeda Sirah; Tsuei-Ju Wu; Xuan Liu; Lan Jin; Kenneth Wu; P Douglas Boatman; Graeme Semple; Dominic P Behan; Daniel T Connolly; Eseng Lai; John A Wagner; Samuel D Wright; Cynthia Cuffie; Yale B Mitchel; Daniel J Rader; John F Paolini; M Gerard Waters; Andrew Plump
Journal:  Sci Transl Med       Date:  2012-08-22       Impact factor: 17.956

9.  Postprandial triglyceride responses to aerobic exercise and extended-release niacin.

Authors:  Eric P Plaisance; Michael L Mestek; A Jack Mahurin; J Kyle Taylor; Jose Moncada-Jimenez; Peter W Grandjean
Journal:  Am J Clin Nutr       Date:  2008-07       Impact factor: 7.045

10.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.

Authors:  Sorin Tunaru; Jukka Kero; Annette Schaub; Christian Wufka; Andree Blaukat; Klaus Pfeffer; Stefan Offermanns
Journal:  Nat Med       Date:  2003-02-03       Impact factor: 53.440

View more
  7 in total

1.  Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Authors:  Tobias Kroon; Tania Baccega; Arne Olsén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

2.  Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.

Authors:  Tobias Kroon; Ann Kjellstedt; Pia Thalén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2015-07-13       Impact factor: 5.922

3.  Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.

Authors:  Richard L Dunbar; Harsh Goel; Sony Tuteja; Wen-Liang Song; Grace Nathanson; Zeeshan Babar; Dusanka Lalic; Joel M Gelfand; Daniel J Rader; Gary L Grove
Journal:  J Lipid Res       Date:  2017-01-23       Impact factor: 5.922

Review 4.  Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.

Authors:  Harsh Goel; Richard L Dunbar
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

Review 5.  Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes.

Authors:  Amélie I S Sobczak; Claudia A Blindauer; Alan J Stewart
Journal:  Nutrients       Date:  2019-08-28       Impact factor: 5.717

6.  mTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia.

Authors:  Lauren M Paolella; Sarmistha Mukherjee; Cassie M Tran; Bruna Bellaver; Mindy Hugo; Timothy S Luongo; Swapnil V Shewale; Wenyun Lu; Karthikeyani Chellappa; Joseph A Baur
Journal:  Mol Metab       Date:  2019-12-13       Impact factor: 7.422

7.  Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin.

Authors:  Sony Tuteja; Liming Qu; Marijana Vujkovic; Richard L Dunbar; Jinbo Chen; Stephanie DerOhannessian; Daniel J Rader
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.